Aberrant microRNA expression implicates on Hepatocellular carcinoma (HCC) development/progression. Conversely, daily coffee consumption reduces by ~40% the risk for fibrosis/cirrhosis and HCC, while decaffeinated coffee does not. Are these beneficial effects related to caffeine (CAF), or to its combination with other common/highly bioavailable coffee compounds, as trigonelline (TRI) and chlorogenic acid (CGA)? We evaluated whether CAF individually or combined with TRI and/or CGA alleviates fibrosis-associated hepatocarcinogenesis, examining the involvement of miRNA profile modulation. Male C3H/HeJ mice were submitted to a diethylnitrosamine/carbon tetrachloride-induced model. Animals received CAF (50 mg/kg body weight, 5x/week, intragastrically), CAF+TRI (50 and 25 mg/kg), CAF+CGA (50 and 25 mg/kg) or CAF+TRI+CGA (50, 25 and 25 mg/kg) for 10 weeks. Only CAF+TRI+CGA treatment reduced hepatocellular preneoplastic foci development. Moreover, only the combination of all compounds reduced proliferation (Ki-67) in preneoplastic lesions and enhanced apoptosis (cleaved caspase-3) in adjacent tissue. CAF+TRI+CGA also decreased hepatic oxidative stress by enhancing antioxidant Nrf2 axis. CAF+TRI+CGA had the most pronounced effects on decreasing hepatic pro-inflammatory IL-17/NFκB signaling, contributing to reduce CD68-positive macrophage number, stellate cell activation and collagen deposition. The miRNAomic profile revealed that CAF+TRI+CGA upregulated tumor suppressors miR-144-3p and antifibrotic miR-15b-5p, frequently altered in HCC. CAF+TRI+CGA reduced protein levels of proproliferative EGFR (miR-144-3p target) and antiapoptotic Bcl-2 family members (Bcl-2, Mcl-1 and Bcl2l2, miR-15b-5p targets). The results suggest that the combination of coffee compounds, rather than CAF individually, attenuates fibrosisassociated hepatocarcinogenesis by modulating miRNA expression profile. Findings provide translational insights on therapeutic approaches based on miRNA profile modulation by coffee compounds.